Search





Search





Markets
/
Stocks
/
nasdaq-snoa
/

Sonoma Pharmaceuticals Inc

SNOA

Add to Watchlist

1.090USD

-0.090-7.63%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

3.79MMarket Cap

LossP/E TTM



Sonoma Pharmaceuticals Inc

1.090

-0.090-7.63%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sonoma Pharmaceuticals Inc

Currency: USD Updated: 2026-05-15

Key Insights

Sonoma Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 14.80.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sonoma Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

63 / 155

Overall Ranking

170 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Sonoma Pharmaceuticals Inc Highlights

StrengthsRisks

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.29M.

Overvalued

The company’s latest PE is -0.56, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 127.80K shares, decreasing 21.35% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

14.800

Target Price

+1154.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Sonoma Pharmaceuticals Inc is 7.55, ranking 100 out of 155 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.35M, representing a year-over-year increase of 22.03%, while its net profit experienced a year-over-year increase of 11.75%.

Score

Industry at a Glance

Previous score

7.55

Change



Financials

5.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.33

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.59

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.27

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Sonoma Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Sonoma Pharmaceuticals Inc is 8.19, ranking 24 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -0.56, which is -83.06% below the recent high of -0.10 and -459.44% above the recent low of -3.14.

Score

Industry at a Glance

Previous score

8.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/155

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Sonoma Pharmaceuticals Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The average price target is 14.80, with a high of 14.80 and a low of 14.80.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Sonoma Pharmaceuticals Inc is 6.42, ranking 114 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.36 and the support level at 0.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.048

Neutral

RSI(14)

31.012

Neutral

STOCH(KDJ)(9,3,3)

22.472

Sell

ATR(14)

0.072

Low Volatility

CCI(14)

-46.248

Neutral

Williams %R

69.565

Sell

TRIX(12,20)

-2.625

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.152

Sell

MA10

1.178

Sell

MA20

1.359

Sell

MA50

1.946

Sell

MA100

2.585

Sell

MA200

3.249

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Sonoma Pharmaceuticals Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 3.68%, representing a quarter-over-quarter decrease of 9.03%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

DRW Securities, LLC

60.98K

+257.22%

Geode Capital Management, L.L.C.

15.91K

-9.70%

McKinley Carter Wealth Services, Inc.

11.19K

Thornton (Bruce)

7.72K

-0.01%

Trombly (Amy Moss)

7.68K

Dvonch (Jerome J)

4.23K

-0.02%

Global Retirement Partners, LLC

772.00

+76.26%

Osaic Holdings, Inc.

500.00

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sonoma Pharmaceuticals Inc is 3.07, ranking 108 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.